Skip to main content
SpringerLink
Log in

Hypertension in Chronic Kidney Disease

  • Chapter
Secondary Hypertension

Part of the book series: Clinical Hypertension and Vascular Diseases ((CHVD))

  • 180 Accesses

Abstract

Hypertension occurs in more than 90% of patients with chronic kidney disease (CKD) during the course of their disease. Hypertension can directly injure the kidney and it is a recognized risk factor for development of end-stage renal disease (ESRD) and accounts for nearly 30% of new cases of ESRD in the United States. Moreover, ESRD attributed to hypertensive nephrosclerosis has been increasing annually about 8% per year, despite reductions in death caused by stroke and myocardial infarction during the same time period. Diabetes and hypertension account for nearly three-fourths of the nearly 400,000 persons currently under treatment for ESRD by dialysis or kidney transplant. It is now recognized that of the factors contributing to hypertensive renal injury, the renin-angiotensin-aldosterone system (RAAS) plays a key role in the development and progression of CKD caused by hypertension, diabetes, and glomerulonephritis. Recent advances in the pathogenesis and treatment of hypertension in CKD are the subject of this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. NIH. U.S. Renal Data System, USRDS 2000 annual data report. 12th annual report. 6–10–0200. Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases.

    Google Scholar 

  2. Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the U.S. population: third National Health and Nutrition Examination Survey [published erratum appears in Am J Kidney Dis 2000 Jan;35(1):1781.

    Google Scholar 

  3. Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the U.S. population: third National Health and Nutrition Examination Survey [published erratum appears in Am J Kidney Dis 1998;32(6):992–999.

    Article  PubMed  CAS  Google Scholar 

  4. The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Int Med 1993;153:154–183.

    Article  Google Scholar 

  5. Wright, JT, Kusek, JW, Toto, RD, et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin. Trials 1996;17:3S-16S.

    Google Scholar 

  6. Joint National Committee on Prevention EaToH. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Int Med 1997;157:2413–2446.

    Article  Google Scholar 

  7. Mailloux LU, Levey AS. Hypertension in patients with chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S120-S141.

    Article  PubMed  CAS  Google Scholar 

  8. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection and Follow-up study. Hypertension 1989;13(suppl I):I80-I93.

    Article  PubMed  CAS  Google Scholar 

  9. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334(1):13–18.

    Article  PubMed  CAS  Google Scholar 

  10. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334(1):13–18. Au Ref 9 duplicates ref 8. Delete ref 9 and renumber here and in text or provide new new ref.

    Article  PubMed  CAS  Google Scholar 

  11. Shulman NB. Epidemiology of hypertension in blacks. In: Hall WD, Saunders E, Shulman NB, ed. Hypertension in Blacks: Epidemiology, pathophysiology and treamtent. Chicago: New York Medical Publishers, 1985: 115–131.

    Google Scholar 

  12. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36: 646–661.

    Article  PubMed  CAS  Google Scholar 

  13. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Eng J Med 2001;345:479–486.

    Article  CAS  Google Scholar 

  14. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 2001;161:1207.

    Article  PubMed  CAS  Google Scholar 

  15. Hebert LA, Wilmer WA, Falkenhain ME, et al. Renoprotection: one or many therapies? Kidney Int 2001;59:1211–1226.

    Article  PubMed  CAS  Google Scholar 

  16. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Intl 2000;57:1803–1817.

    Article  CAS  Google Scholar 

  17. Toto R. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med 2001;161:1492–1499.

    Article  PubMed  CAS  Google Scholar 

  18. Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease [clinical conference]. Kidney Int 1983;23(4):647–655.

    Article  PubMed  CAS  Google Scholar 

  19. Bennett PH, Haffner S, Kasiske BL, et al. Diabetic renal disease recommendations. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the scientific advisory board of the National Kidney Foundation from an ad hoc committee of the council on diabetes mellitus of the National Kidney Foundation. Am J Kid Dis 1995;25:107–112.

    Article  PubMed  CAS  Google Scholar 

  20. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995;346(8982):1080–1084.

    Article  PubMed  CAS  Google Scholar 

  21. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000 Feb;57(2):601–606.

    Article  PubMed  CAS  Google Scholar 

  22. Nelson RG, Tan M, Beck GJ, et al. Changing glomerular filtration with progression from impaired glucose tolerance to type II diabetes mellitus. Diabetologia 1999;42(1):90–93.

    Article  PubMed  CAS  Google Scholar 

  23. Nelson RG, Meyer TW, Myers BD, Bennett PH. Course of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Kidney Int Suppl 1997; 63:S45-S48.

    PubMed  CAS  Google Scholar 

  24. Blouch K, Deen WM, Fauvel JP, Bialek J, Derby G, Myers BD. Molecular configuration and glomerular size selectivity in healthy and nephrotic humans. Am J Physiol 1997;273(3 Pt 2):F430-F437.

    PubMed  CAS  Google Scholar 

  25. Lemley KV, Blouch K, Abdullah I, et al. Glomerular permselectivity at the onset of nephropathy in Type 2 diabetes mellitus. J Am Soc Nephrol 2000;11:2095–2105.

    PubMed  CAS  Google Scholar 

  26. Nelson RG, Bennett PH, Beck GJ, et al. for the Diabetic Renal Disease Study Group. Development and progression of renal disease in Pima Indians with non- insulindependent diabetes mellitus. N Engl J Med 1996;335(22):1636–1642.

    Article  PubMed  CAS  Google Scholar 

  27. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51(6):1908–1919.

    Article  PubMed  CAS  Google Scholar 

  28. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl Med 1988;318:1657–1666.

    Article  CAS  Google Scholar 

  29. Klahr S. Low protein diets and angiotensin-converting enzyme inhibition in progressive renal failure. Am J Kid Dis 1993 ;22(1):114–119.

    PubMed  CAS  Google Scholar 

  30. Klahr S, Levey A, Beck G, et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl JMed 1994;330:877–884.

    Article  CAS  Google Scholar 

  31. Peterson JC, Adler S, Burkart JM, et al. For the Modification of Diet in Renal Disease Study. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995;123(10):754–762.

    Article  PubMed  CAS  Google Scholar 

  32. Klahr S, Breyer JA, Beck GJ, et al. for the Modification of Diet in Renal Disease Study Group Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. [published erratum appears in J Am Soc Nephrol 1995 Oct;6(4):1318]. J Am Soc Nephrol 1995;5(12):2037–2047.

    CAS  Google Scholar 

  33. Klahr S. Role of dietary protein and blood pressure in the progression of renal disease. Kidney Int 1996;49(6):1783–1786.

    Article  PubMed  CAS  Google Scholar 

  34. Benigni A, Remuzzi G. How renal cytokines and growth factors contribute to renal disease progression. Am J Kidney Dis 2001;37:S21-S24.

    Article  PubMed  CAS  Google Scholar 

  35. Ruggenenti P, Perna A, Benini R, Remuzzi G. for the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol 1998;9(11):2096–2101.

    PubMed  CAS  Google Scholar 

  36. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000;35(6): 1155–1165.

    Article  PubMed  CAS  Google Scholar 

  37. Ruggenenti P, Perna A, Benini R, et al. for the Gruppo Italiano Studi Epidemiologici in Nefrologia (GISEN). In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. J Am Soc Nephrol 1999;10(5):997–1006.

    PubMed  CAS  Google Scholar 

  38. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. for the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Ramipril Efficacy in Nephropathy [see comments]. Lancet 1998;352(9136):1252–1256.

    Article  PubMed  CAS  Google Scholar 

  39. Ruggenenti P, Perna A, Mosconi L, et al. for the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. Kidney Int Suppl 1997;63:S54-S57.

    PubMed  CAS  Google Scholar 

  40. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339(20):1448–1456.

    Article  PubMed  CAS  Google Scholar 

  41. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease [see comments]. Am J Kidney Dis 2000;35(3):427–432.

    Article  PubMed  CAS  Google Scholar 

  42. Plum J, Bunten B, Nemeth R, Grabensee B. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.

    Google Scholar 

  43. Myers BD, Nelson RG, Tan M, et al. Progression of overt nephropathy in noninsulin-dependent diabetes. Kidney Int 1995;47(6):1781–1789.

    Article  PubMed  CAS  Google Scholar 

  44. Austin SM, Lieberman JS, Newton LD, Mejia M, Peters WA, Myers BD. Slope of serial glomerular filtration rate and the progression of diabetic glomerular disease. J Am Soc Nephrol 1993;3(7):1358–1370.

    PubMed  CAS  Google Scholar 

  45. The HOPE Trial (Heart Outcomes Prevention Evaluation Study) Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators [see comments]. Lancet 2000;355(9200):253–259.

    Google Scholar 

  46. Toto RD, Adams-Huet B, Fenves AZ, Mitchell HC, Mulcahy W, Smith RD. Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria. Am J Kidney Dis 1996;28(6):832–840.

    Article  PubMed  CAS  Google Scholar 

  47. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/ calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54(4): 1283–1289.

    Article  PubMed  CAS  Google Scholar 

  48. Bakris GL, Griffin KA, Picken MM, Bidani AK. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens 1997;15(10):1181–1185.

    Article  PubMed  CAS  Google Scholar 

  49. Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and beta blockers in non- diabetic chronic renal failure. Br Med J 1994;309(6958):833–837.

    Article  CAS  Google Scholar 

  50. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis 1996;27(4):489–495.

    Article  PubMed  CAS  Google Scholar 

  51. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118(8):577–581.

    Article  PubMed  CAS  Google Scholar 

  52. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001;135:73–87.

    Article  PubMed  CAS  Google Scholar 

  53. MaGee JH, Unger AM, Richardson DW. Changes in renal function associated with drug or placebo therapy of human hypertension. Am J Med 1964;36:795–804.

    Article  PubMed  CAS  Google Scholar 

  54. Moyer JH, Heider C, Pevey K, Ford RV. The effect of treatment on the vascular deterioration associated with hypertension, with particular emphasis on renal function. Am J Med 1958;24:177–192.

    Article  PubMed  CAS  Google Scholar 

  55. Peterson JC, Adler S, Burkart JM, et al. for the Modification of Diet in Renal Disease Study. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995;123(10):754–762.

    Article  PubMed  CAS  Google Scholar 

  56. Viberti G, Morgensen GCE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitius and microalbuminuria. J Am Med Assoc 1994;271:275–279.

    Article  CAS  Google Scholar 

  57. Hebert LA, Bain RP, Verme D, et al. Remission of nephrotic reange proteinuria in Type 1 diabetes. Kidney Int 1994;46:1688–1693. Au Term ok?

    Article  PubMed  CAS  Google Scholar 

  58. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50(5):1641–1650.

    Article  PubMed  CAS  Google Scholar 

  59. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54(3):889–896.

    Article  PubMed  CAS  Google Scholar 

  60. GISEN. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. [see comments]. Lancet 1997;349(9069):1857–1863.

    Article  Google Scholar 

  61. Maschio G, Alberti D, Janin G, et al. for the Angiotensin-Converting- Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334(15):939–945.

    Article  PubMed  CAS  Google Scholar 

  62. Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA. “Strict” blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 1995;48(3):851–859.

    Article  PubMed  CAS  Google Scholar 

  63. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensives: a randomized controlled trial. JAMA 2001; 285(2719):2728.

    Google Scholar 

  64. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med. 2001;134(5):370–379.

    Google Scholar 

  65. Lewis E, Hunsicker LG, Bain RP, Rohde RD, the Collaborative Study Group. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl Med 1993;329:1456–1462.

    Article  CAS  Google Scholar 

  66. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with type 2 Diabetes. N Engl J Med 2001;345:870–878.

    Article  PubMed  CAS  Google Scholar 

  67. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. The RENAAL Study Investigators N Engl J Med 2001;345:861–869.

    Article  CAS  Google Scholar 

  68. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. The Collaborative Study Group. N Engl J Med 2001;345:851–860.

    Article  PubMed  CAS  Google Scholar 

  69. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. [see comments] [published erratum appears in Br Med J 1999;318(7175):29].

    Google Scholar 

  70. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. Br Med J 1998;317(7160):703–713.

    Article  Google Scholar 

  71. Smith AC, Toto RD, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Intl 1998;54:889–896.

    Article  CAS  Google Scholar 

  72. Ruggenenti P, Perna A, Benini R, Remuzzi G for the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol 1998;9:2096–2101.

    PubMed  CAS  Google Scholar 

  73. Hostetter TH, Rosenberg ME, Ibrahim HN, Juknevicius I. Aldosterone in renal disease. Curr Opin Nephrol Hypertens 2001;10:105–110

    Article  PubMed  CAS  Google Scholar 

  74. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med , 2001;345: 925–926.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Robert D. Toto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, CT, USA

    George A. Mansoor MD, FRCP (EDIN)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Toto, R.D. (2004). Hypertension in Chronic Kidney Disease. In: Mansoor, G.A. (eds) Secondary Hypertension. Clinical Hypertension and Vascular Diseases. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-757-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-757-4_3

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-383-1

  • Online ISBN: 978-1-59259-757-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation